

Derek M Yellon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1337135/derek-m-yellon-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

234 papers	28,498 citations	88 h-index	166 g-index
292 ext. papers	31,847 ext. citations	8.3 avg, IF	7.6 L-index

#	Paper	IF	Citations
234	Do We Really Need Aspirin Loading for STEMI?. <i>Cardiovascular Drugs and Therapy</i> , 2022 , 1	3.9	0
233	Remote Ischaemic Conditioning in STEMI Patients in Sub-Saharan AFRICA: Rationale and Study Design for the RIC-AFRICA Trial. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	1
232	Effect of remote ischaemic conditioning on infarct size and remodelling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. <i>Basic Research in Cardiology</i> , 2021 , 116, 59	11.8	3
231	Extracellular histones are a target in myocardial ischaemia reperfusion injury. <i>Cardiovascular Research</i> , 2021 ,	9.9	4
230	Exosomes from neuronal stem cells may protect the heart from ischaemia/reperfusion injury via JAK1/2 and gp130. <i>Journal of Cellular and Molecular Medicine</i> , 2021 , 25, 4455-4465	5.6	4
229	Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke. <i>Basic Research in Cardiology</i> , 2021 , 116, 32	11.8	8
228	RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19. <i>Cardiovascular Drugs and Therapy</i> , 2021 , 1	3.9	0
227	Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial. <i>Cardiovascular Research</i> , 2021 , 117, 623-634	9.9	7
226	Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response. <i>Basic Research in Cardiology</i> , 2021 , 116, 12	11.8	16
225	IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. <i>Basic Research in Cardiology</i> , 2021 , 116, 52	11.8	11
224	Hydralazine protects the heart against acute ischemia/reperfusion injury by inhibiting Drp1-mediated mitochondrial fission. <i>Cardiovascular Research</i> , 2021 ,	9.9	7
223	Small extracellular vesicles secreted from human amniotic fluid mesenchymal stromal cells possess cardioprotective and promigratory potential. <i>Basic Research in Cardiology</i> , 2020 , 115, 26	11.8	38
222	The cytokine storm of COVID-19: a spotlight on prevention and protection. <i>Expert Opinion on Therapeutic Targets</i> , 2020 , 24, 723-730	6.4	55
221	Increased production of functional small extracellular vesicles in senescent endothelial cells. <i>Journal of Cellular and Molecular Medicine</i> , 2020 , 24, 4871-4876	5.6	19
220	The Role of Extracellular DNA and Histones in Ischaemia-Reperfusion Injury of the Myocardium. <i>Cardiovascular Drugs and Therapy</i> , 2020 , 34, 123-131	3.9	12
219	Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?. <i>Neural Regeneration Research</i> , 2020 , 15, 1852-1853	4.5	3
218	Mouse models of atherosclerosis and their suitability for the study of myocardial infarction. <i>Basic Research in Cardiology</i> , 2020 , 115, 73	11.8	14

217	The importance of clinically relevant background therapy in cardioprotective studies. <i>Basic Research in Cardiology</i> , 2020 , 115, 69	11.8	9
216	Neuroprotection by remote ischemic conditioning in the setting of acute ischemic stroke: a preclinical two-centre study. <i>Scientific Reports</i> , 2020 , 10, 16874	4.9	8
215	Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial. <i>Lancet, The</i> , 2019 , 394, 1415-1424	12.5	125
214	SGLT2 Inhibitor, Canagliflozin, Attenuates Myocardial Infarction in the Diabetic and Nondiabetic Heart. <i>JACC Basic To Translational Science</i> , 2019 , 4, 15-26	8.7	50
213	Stromal cell-derived factor-1 signals via the endothelium to protect the heart against ischaemia-reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2019 , 128, 187-197	5.8	13
212	Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 661-667	3.9	19
211	Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. <i>Cardiovascular Diabetology</i> , 2019 , 18, 168	8.7	15
210	Role of Caspase 1 in Ischemia/Reperfusion Injury of the Myocardium. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 194-200	3.1	25
209	Comparison of small extracellular vesicles isolated from plasma by ultracentrifugation or size-exclusion chromatography: yield, purity and functional potential. <i>Journal of Extracellular Vesicles</i> , 2019 , 8, 1560809	16.4	148
208	Multitarget Strategies to Reduce Myocardial Ischemia/Reperfusion Injury: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 89-99	15.1	292
207	Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 127-133	3.9	10
206	The GTN patch: a simple and effective new approach to cardioprotection?. <i>Basic Research in Cardiology</i> , 2018 , 113, 20	11.8	15
205	The Caspase 1 Inhibitor VX-765 Protects the Isolated Rat Heart via the RISK Pathway. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 165-168	3.9	28
204	Therapeutic strategies utilizing SDF-1 in ischaemic cardiomyopathy. <i>Cardiovascular Research</i> , 2018 , 114, 358-367	9.9	26
203	SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. <i>Lancet Diabetes and Endocrinology, the</i> , 2018 , 6, 435-437	18.1	30
202	Cardioprotection mediated by exosomes is impaired in the setting of type II diabetes but can be rescued by the use of non-diabetic exosomes in vitro. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 141-151	5.6	62
201	Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. <i>Basic Research in Cardiology</i> , 2018 , 113, 39	11.8	224
200	Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. <i>Basic Research in Cardiology</i> , 2018 , 113, 25	11.8	46

199	Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. <i>Journal of Cellular and Molecular Medicine</i> , 2018 , 22, 926-935	5.6	24
198	The RISK pathway and beyond. <i>Basic Research in Cardiology</i> , 2018 , 113, 2	11.8	110
197	Exosomes and cardioprotection - A critical analysis. <i>Molecular Aspects of Medicine</i> , 2018 , 60, 104-114	16.7	61
196	Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning. <i>Scientific Reports</i> , 2018 , 8, 15885	4.9	59
195	Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway. <i>Cardiovascular Drugs and Therapy</i> , 2018 , 32, 245-253	3.9	12
194	Anthracycline Chemotherapy and Cardiotoxicity. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 63-75	3.9	418
193	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2017 , 113, 564-585	9.9	206
192	Ventilation strategy has a major influence on remote ischaemic preconditioning in mice. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 2426-2431	5.6	2
191	Apoptosis, A Double-Edge Sword!. <i>JACC Basic To Translational Science</i> , 2017 , 2, 498	8.7	
190	The role of PI3K β isoform in cardioprotection. <i>Basic Research in Cardiology</i> , 2017 , 112, 66	11.8	42
189	A novel recombinant antibody specific to full-length stromal derived factor-1 for potential application in biomarker studies. <i>PLoS ONE</i> , 2017 , 12, e0174447	3.7	4
188	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. <i>Cardiovascular Research</i> , 2017 , 113, 1418-1419	9.9	9
187	Confounding factors in vesicle uptake studies using fluorescent lipophilic membrane dyes. <i>Journal of Extracellular Vesicles</i> , 2017 , 6, 1388731	16.4	102
186	Exosomes and Cardiovascular Protection. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 77-86	3.9	60
185	193 The role of the pi3k-alpha isoform in cardioprotection. <i>Heart</i> , 2017 , 103, A131.2-A131	5.1	
184	Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. <i>Cardiovascular Research</i> , 2017 , 113, 288-297	9.9	58
183	Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. <i>European Heart Journal</i> , 2017 , 38, 935-941	9.5	167
182	Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality. <i>Heart</i> , 2017 ,	5.1	12

181	Characterization of the Langendorff Perfused Isolated Mouse Heart Model of Global Ischemia-Reperfusion Injury: Impact of Ischemia and Reperfusion Length on Infarct Size and LDH Release. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016 , 21, 286-95	2.6	39
180	Cardioprotection: The Disconnect Between Bench and Bedside. <i>Circulation</i> , 2016 , 134, 574-5	16.7	36
179	From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on "New frontiers in cardiovascular research". <i>Basic Research in Cardiology</i> , 2016 , 111, 69	11.8	36
178	Ischaemic conditioning and targeting reperfusion injury: a 30-year voyage of discovery. <i>Basic Research in Cardiology</i> , 2016 , 111, 70	11.8	192
177	Exogenous Administration of Recombinant MIF at Physiological Concentrations Failed to Attenuate Infarct Size in a Langendorff Perfused Isolated Mouse Heart Model. <i>Cardiovascular Drugs and Therapy</i> , 2016 , 30, 445-453	3.9	15
176	Co-dependence of the neural and humoral pathways in the mechanism of remote ischemic conditioning. <i>Basic Research in Cardiology</i> , 2016 , 111, 50	11.8	68
175	Reducing myocardial infarct size: challenges and future opportunities. <i>Heart</i> , 2016 , 102, 341-8	5.1	135
174	Microvesicles and exosomes: new players in metabolic and cardiovascular disease. <i>Journal of Endocrinology</i> , 2016 , 228, R57-71	4.7	220
173	Ischaemic conditioning and reperfusion injury. <i>Nature Reviews Cardiology</i> , 2016 , 13, 193-209	14.8	307
172	Quantifying the Area at Risk in Reperfused ST-Segment-Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomography-Magnetic Resonance Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9, e003900	3.9	42
171	Dexmedetomidine protects the heart against ischemia-reperfusion injury by an endothelial eNOS/NO dependent mechanism. <i>Pharmacological Research</i> , 2016 , 103, 318-27	10.2	48
170	Effect of Remote Ischaemic preconditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial. <i>Efficacy and Mechanism Evaluation</i> , 2016 , 3, 1-58	1.7	4
169	A critical review on the translational journey of cardioprotective therapies!. <i>International Journal of Cardiology</i> , 2016 , 220, 176-84	3.2	25
168	162 Polymersomes Functionalized with HSP70 [Novel, Synthetic Cardioprotective Nanovesicles. <i>Heart</i> , 2016 , 102, A115.2-A115	5.1	7
167	Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment-Elevation Myocardial Infarction and Adverse Left Ventricular Remodeling. <i>Circulation: Cardiovascular Imaging</i> , 2016 , 9,	3.9	74
166	Effect of Remote Ischaemic Conditioning in Oncology Patients Undergoing Chemotherapy: Rationale and Design of the ERIC-ONC Study--A Single-Center, Blinded, Randomized Controlled Trial. <i>Clinical Cardiology</i> , 2016 , 39, 72-82	3.3	16
165	Promising strategies to minimize reperfusion injury in STEMI. <i>Minerva Cardioangiologica</i> , 2016 , 64, 284-94	1	1
164	Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. <i>Basic Research in Cardiology</i> , 2015 , 110, 453	11.8	85

163	Plasma exosomes protect the myocardium from ischemia-reperfusion injury. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1525-36	15.1	323
162	Pharmacological cardioprotection in diabetes. <i>Diabetes Management</i> , 2015 , 5, 89-101	0	
161	The pleiotropic effects of metformin: time for prospective studies. <i>Cardiovascular Diabetology</i> , 2015 , 14, 109	8.7	22
160	The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the ERIC-GTN Study. <i>Clinical Cardiology</i> , 2015 , 38, 641-6	3.3	12
159	From Protecting the Heart to Improving Athletic Performance - the Benefits of Local and Remote Ischaemic Preconditioning. <i>Cardiovascular Drugs and Therapy</i> , 2015 , 29, 573-588	3.9	28
158	Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. <i>New England Journal of Medicine</i> , 2015 , 373, 1408-17	59.2	465
157	Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2764-5	15.1	63
156	Inhibition of NAADP signalling on reperfusion protects the heart by preventing lethal calcium oscillations via two-pore channel 1 and opening of the mitochondrial permeability transition pore. <i>Cardiovascular Research</i> , 2015 , 108, 357-66	9.9	29
155	Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 178-188	5	167
154	Effect of remote ischaemic preconditioning on clinical outcomes in patients undergoing cardiac bypass surgery: a randomised controlled clinical trial. <i>Heart</i> , 2015 , 101, 185-92	5.1	137
153	Remote ischaemic preconditioning for coronary artery bypass grafting 2015 ,		1
152	Evaluating early and delayed cardioprotection by plasma exosomes in simulated ischaemia-reperfusion injury. <i>Bioscience Horizons</i> , 2015 , 8,		1
151	Remote ischemic conditioning. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 177-95	15.1	391
150	Effect of remote ischaemic conditioning on clinical outcomes in patients presenting with an ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1846-8	9.5	50
149	Effect of remote ischaemic conditioning on contrast-induced nephropathy in patients undergoing elective coronary angiography (ERICCIN): rationale and study design of a randomised single-centre, double-blind placebo-controlled trial. <i>Clinical Research in Cardiology</i> , 2014 , 103, 203-9	6.1	19
148	Cardiovascular remodelling in coronary artery disease and heart failure. <i>Lancet, The</i> , 2014 , 383, 1933-43	40	469
147	Exosomes: nanoparticles involved in cardioprotection?. <i>Circulation Research</i> , 2014 , 114, 325-32	15.7	132
146	Endothelial insulin resistance protects the heart against prolonged ischemia-reperfusion injury but does not prevent insulin transport across the endothelium in a mouse Langendorff model. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 586-91	2.6	6

145	β adrenergic receptor selective stimulation during ischemia/reperfusion improves cardiac function in translational models through inhibition of mPTP opening in cardiomyocytes. <i>Basic Research in Cardiology</i> , 2014 , 109, 422	11.8	49
144	Stromal derived factor 1βa chemokine that delivers a two-pronged defence of the myocardium. <i>Pharmacology & Therapeutics</i> , 2014 , 143, 305-15	13.9	67
143	Characterization of acute ischemia-related physiological responses associated with remote ischemic preconditioning: a randomized controlled, crossover human study. <i>Physiological Reports</i> , 2014 , 2, e12200	2.6	32
142	224 Stromal Derived Factor 1 Alpha is a Mediator of Conditioning in Human and Rat Myocardium. <i>Heart</i> , 2014 , 100, A121.2-A122	5.1	1
141	ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. <i>Cardiovascular Research</i> , 2014 , 104, 399-411	9.9	108
140	A retrospective analysis of myocardial preservation techniques during coronary artery bypass graft surgery: are we protecting the heart?. <i>Journal of Cardiothoracic Surgery</i> , 2014 , 9, 184	1.6	11
139	Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 83-96	2.6	62
138	Matrix metalloproteinase inhibition protects CyPD knockout mice independently of RISK/mPTP signalling: a parallel pathway to protection. <i>Basic Research in Cardiology</i> , 2013 , 108, 331	11.8	19
137	Remote ischaemic preconditioning involves signalling through the SDF-1/CXCR4 signalling axis. <i>Basic Research in Cardiology</i> , 2013 , 108, 377	11.8	105
136	Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013 , 18, 263-9	2.6	29
135	Myocardial reperfusion injury: looking beyond primary PCI. <i>European Heart Journal</i> , 2013 , 34, 1714-22	9.5	252
134	Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. <i>Cardiovascular Diabetology</i> , 2013 , 12, 154	8.7	70
133	Surgery: Remote ischaemic conditioning--approaching prime time?. <i>Nature Reviews Cardiology</i> , 2013 , 10, 619-21	14.8	2
132	Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. <i>Cardiovascular Drugs and Therapy</i> , 2013 , 27, 5-16	3.9	74
131	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2013 , 98, 7-27	9.9	172
130	Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling. <i>Cardiovascular Research</i> , 2013 , 99, 694-704	9.9	65
129	Myocardial ischemia-reperfusion injury: a neglected therapeutic target. <i>Journal of Clinical Investigation</i> , 2013 , 123, 92-100	15.9	1250
128	Contrast-induced acute kidney injury following PCI. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 483-90	4.6	47

127	Loss of PINK1 increases the heart's vulnerability to ischemia-reperfusion injury. <i>PLoS ONE</i> , 2013 , 8, e62409	9.9	79
126	Preconditioning in the Heart 2013 , 51-101		
125	Cardioprotection during cardiac surgery. <i>Cardiovascular Research</i> , 2012 , 94, 253-65	9.9	100
124	Conditioning the whole heart--not just the cardiomyocyte. <i>Journal of Molecular and Cellular Cardiology</i> , 2012 , 53, 24-32	5.8	49
123	The Akt1 isoform is an essential mediator of ischaemic preconditioning. <i>Journal of Cellular and Molecular Medicine</i> , 2012 , 16, 1739-49	5.6	28
122	Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. <i>Clinical Research in Cardiology</i> , 2012 , 101, 339-48	6.1	75
121	The diabetic heart: too sweet for its own good?. <i>Cardiology Research and Practice</i> , 2012 , 2012, 845698	1.9	44
120	Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 1153-75	4	59
119	STAT5 fits the RISK profile for cardioprotection. <i>Jak-stat</i> , 2012 , 1, 73-6		3
118	Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. <i>Cardiovascular Research</i> , 2012 , 93, 445-53	9.9	59
117	Myocardial Reperfusion Injury as a New Frontier for Clinical Therapy 2012 , 3-8		
116	Novel Treatment Strategies 2012 , 261-291		
115	Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. <i>Antioxidants and Redox Signaling</i> , 2011 , 14, 893-907	8.4	149
114	Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 2011 , 50, 940-50	5.8	290
113	Remote ischemic conditioning: a clinical trial's update. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011 , 16, 304-12	2.6	40
112	There is more to life than revascularization: therapeutic targeting of myocardial ischemia/reperfusion injury. <i>Cardiovascular Therapeutics</i> , 2011 , 29, e67-79	3.3	35
111	Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 2443-51	5.6	52
110	Necroptosis, necrostatins and tissue injury. <i>Journal of Cellular and Molecular Medicine</i> , 2011 , 15, 1797-805	5.6	56

109	Adipocytokines, cardiovascular pathophysiology and myocardial protection. <i>Pharmacology & Therapeutics</i> , 2011 , 129, 206-19	13.9	63
108	The therapeutic potential of ischemic conditioning: an update. <i>Nature Reviews Cardiology</i> , 2011 , 8, 619-24	14.8	177
107	Failure to recapture cardioprotection with high-dose atorvastatin in coronary artery bypass surgery: a randomised controlled trial. <i>Basic Research in Cardiology</i> , 2011 , 106, 1387-95	11.8	16
106	Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. <i>European Heart Journal</i> , 2011 , 32, 23-31	9.5	131
105	Failure of the adipocytokine, resistin, to protect the heart from ischemia-reperfusion injury. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2011 , 16, 63-71	2.6	9
104	Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. <i>Heart</i> , 2011 , 97, 1560-5	5.1	60
103	New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. <i>Circulation</i> , 2011 , 124, 1172-9	16.7	175
102	Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 300, H2123-34	5.2	101
101	Reply to Landoni et al.. <i>European Journal of Cardio-thoracic Surgery</i> , 2010 , 37, 983-983	3	
100	Cardiac preconditioning for ischaemia: lost in translation. <i>DMM Disease Models and Mechanisms</i> , 2010 , 3, 35-8	4.1	96
99	Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. <i>Circulation</i> , 2010 , 121, 1212-22	16.7	696
98	Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. <i>Cardiovascular Research</i> , 2010 , 87, 406-23	9.9	410
97	Preconditioning the diabetic human myocardium. <i>Journal of Cellular and Molecular Medicine</i> , 2010 , 14, 1740-6	5.6	64
96	The neural and humoral pathways in remote limb ischemic preconditioning. <i>Basic Research in Cardiology</i> , 2010 , 105, 651-5	11.8	180
95	Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 25-32	3.9	64
94	The second window of preconditioning (SWOP) where are we now?. <i>Cardiovascular Drugs and Therapy</i> , 2010 , 24, 235-54	3.9	117
93	Cardioprotective growth factors. <i>Cardiovascular Research</i> , 2009 , 83, 179-94	9.9	70
92	Urocortin: a few inflammatory remarks. <i>Endocrinology</i> , 2009 , 150, 5205-7	4.8	2

91	Myocardial protection: is primary PCI enough?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2009 , 6, 12-3		9
90	'Conditioning' the heart during surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 2009 , 35, 977-87	3	31
89	Corrigendum to 'Conditioning' the heart during surgery [Eur. J. Cardiothorac. Surg. 35 (6) (2009) 977-987]. <i>European Journal of Cardio-thoracic Surgery</i> , 2009 , 36, 608-608	3	
88	Statins and cardioprotection--more than just lipid lowering?. <i>Pharmacology & Therapeutics</i> , 2009 , 122, 30-43	13.9	138
87	The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. <i>Basic Research in Cardiology</i> , 2009 , 104, 189-202	11.8	215
86	The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. <i>Basic Research in Cardiology</i> , 2009 , 104, 781-92	11.8	32
85	The divergent roles of protein kinase C epsilon and delta in simulated ischaemia-reperfusion injury in human myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 2009 , 46, 758-64	5.8	36
84	Urocortin: a protective peptide that targets both the myocardium and vasculature. <i>Pharmacological Reports</i> , 2009 , 61, 172-82	3.9	26
83	The cardioprotective actions of leptin are lost in the Zucker obese (fa/fa) rat. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 53, 311-7	3.1	15
82	Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 53, 373-8	3.1	61
81	The novel adipocytokine visfatin exerts direct cardioprotective effects. <i>Journal of Cellular and Molecular Medicine</i> , 2008 , 12, 1395-403	5.6	109
80	Using multiphoton microscopy to examine the response of the heart to ischaemia and reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 44, 778	5.8	
79	The cardioprotective effect of atorvastatin: is there a role for the adenosine receptor?. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 44, 778-779	5.8	1
78	Rho-kinase mediates reoxygenation-induced cardiomyocyte death and promotes mitochondrial transition pore opening. <i>Journal of Molecular and Cellular Cardiology</i> , 2008 , 44, 791-792	5.8	
77	Erythropoietin: ready for prime-time cardioprotection. <i>Trends in Pharmacological Sciences</i> , 2008 , 29, 258-62	5.7	54
76	GLP-1 therapy: beyond glucose control. <i>Circulation: Heart Failure</i> , 2008 , 1, 147-9	7.6	29
75	Remote ischaemic preconditioning: underlying mechanisms and clinical application. <i>Cardiovascular Research</i> , 2008 , 79, 377-86	9.9	372
74	Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. <i>Circulation Research</i> , 2008 , 103, 307-14	15.7	103

73	Mitochondrial PINK1--a novel cardioprotective kinase?. <i>Cardiovascular Drugs and Therapy</i> , 2008 , 22, 507-8	9	
72	Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. <i>Basic Research in Cardiology</i> , 2008 , 103, 274-84	11.8	165
71	Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency. <i>Basic Research in Cardiology</i> , 2008 , 103, 560-8	11.8	58
70	Preconditioning and postconditioning: united at reperfusion 2007 , 116, 173-91		214
69	Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. <i>Heart Failure Reviews</i> , 2007 , 12, 217-34	5	379
68	Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 253-6	3.9	99
67	Necrostatin: a potentially novel cardioprotective agent?. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 227-33	3.9	251
66	Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. <i>Cardiovascular Drugs and Therapy</i> , 2007 , 21, 409-14	3.9	39
65	Ischemic preconditioning targets the reperfusion phase. <i>Basic Research in Cardiology</i> , 2007 , 102, 445-52	11.8	70
64	Postconditioning protects human atrial muscle through the activation of the RISK pathway. <i>Basic Research in Cardiology</i> , 2007 , 102, 453-9	11.8	88
63	Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. <i>Basic Research in Cardiology</i> , 2007 , 102, 518-28	11.8	164
62	Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. <i>Cardiovascular Research</i> , 2007 , 75, 530-5	9.9	204
61	The metabolic syndrome raises the threshold for cardioprotection. <i>Journal of Molecular and Cellular Cardiology</i> , 2007 , 42, S185	5.8	2
60	Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. <i>Lancet, The</i> , 2007 , 370, 575-9	40	524
59	Myocardial reperfusion injury. <i>New England Journal of Medicine</i> , 2007 , 357, 1121-35	59.2	2601
58	Survival kinases in ischemic preconditioning and postconditioning. <i>Cardiovascular Research</i> , 2006 , 70, 240-53	9.9	381
57	Postconditioning for protection of the infarcting heart. <i>Lancet, The</i> , 2006 , 367, 456-8	40	51
56	Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. <i>International Journal of Biochemistry and Cell Biology</i> , 2006 , 38, 414-9	5.6	152

55	Postconditioning does not protect the diabetic heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2006 , 40, 958	5.8	4
54	A potential role for PTEN in the diabetic heart. <i>Cardiovascular Drugs and Therapy</i> , 2006 , 20, 319-21	3.9	23
53	Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten?. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 1287-91	15.1	118
52	Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 288, H971-6	5.2	378
51	Atorvastatin and myocardial reperfusion injury: new pleiotropic effect implicating multiple prosurvival signaling. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 45, 247-52	3.1	62
50	The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. <i>Trends in Cardiovascular Medicine</i> , 2005 , 15, 69-75	6.9	343
49	Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. <i>Cardiovascular Drugs and Therapy</i> , 2005 , 19, 9-11	3.9	101
48	Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. <i>Circulation</i> , 2005 , 112, 2085-8	16.7	104
47	Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 289, H237-42	5.2	112
46	Preconditioning the diabetic heart: the importance of Akt phosphorylation. <i>Diabetes</i> , 2005 , 54, 2360-4	0.9	215
45	Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. <i>Diabetes</i> , 2005 , 54, 146-51	0.9	498
44	Pioglitazone mimics preconditioning in the isolated perfused rat heart: a role for the prosurvival kinases PI3K and P42/44MAPK. <i>Journal of Cardiovascular Pharmacology</i> , 2005 , 46, 817-22	3.1	59
43	Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. <i>Circulation</i> , 2004 , 109, 1714-7	16.7	296
42	Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. <i>Cardiovascular Research</i> , 2004 , 63, 305-12	9.9	141
41	Preconditioning protects by inhibiting the mitochondrial permeability transition. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004 , 287, H841-9	5.2	182
40	Adenosine-induced second window of protection is mediated by inhibition of mitochondrial permeability transition pore opening at the time of reperfusion. <i>Cardiovascular Drugs and Therapy</i> , 2004 , 18, 79-80	3.9	5
39	Heat shock protein 27 protects the heart against myocardial infarction. <i>Basic Research in Cardiology</i> , 2004 , 99, 392-4	11.8	101
38	Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. <i>Circulation Research</i> , 2004 , 95, 230-2	15.7	550

37	New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. <i>Cardiovascular Research</i> , 2004 , 61, 448-60	9.9	740
36	Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. <i>Cardiovascular Research</i> , 2003 , 60, 617-25	9.9	297
35	Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2. <i>Cardiovascular Drugs and Therapy</i> , 2003 , 17, 415-25	3.9	45
34	Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 508-15	15.1	194
33	Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. <i>Journal of the American College of Cardiology</i> , 2003 , 41, 1404-7	15.1	81
32	Preconditioning the myocardium: from cellular physiology to clinical cardiology. <i>Physiological Reviews</i> , 2003 , 83, 1113-51	47.9	838
31	Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. <i>Journal of Molecular and Cellular Cardiology</i> , 2003 , 35, 185-93	5.8	146
30	Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. <i>Journal of Molecular and Cellular Cardiology</i> , 2003 , 35, 1063-71	5.8	78
29	Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 283, H1481-8	5.2	116
28	Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning?. <i>Cardiovascular Research</i> , 2002 , 55, 534-43	9.9	394
27	Preconditioning and arrhythmias. <i>Circulation</i> , 2002 , 106, 2999-3001	16.7	18
26	Mitochondrial K(ATP) channels: role in cardioprotection. <i>Cardiovascular Research</i> , 2002 , 55, 429-37	9.9	142
25	Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS?. <i>Cardiovascular Research</i> , 2002 , 53, 405-13	9.9	36
24	PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. <i>Journal of Molecular and Cellular Cardiology</i> , 2002 , 34, 661-8	5.8	143
23	Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. <i>Circulation</i> , 2001 , 103, 3111-6	16.7	110
22	Cardioprotective effects of transforming growth factor-beta1 during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 930-9	3.1	87
21	Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. <i>Circulation Research</i> , 2001 , 89, 1191-8	15.7	443
20	Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1996-2001	15.1	36

19	Bradykinin elicits "second window" myocardial protection in rat heart through an NO-dependent mechanism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 281, H1458-64	5.2	21
18	Effect of aging on the ability of preconditioning to protect rat hearts from ischemia-reperfusion injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001 , 281, H1630-6	5.2	130
17	Adenosine A(1) receptor induced delayed preconditioning in rabbits: induction of p38 mitogen-activated protein kinase activation and Hsp27 phosphorylation via a tyrosine kinase- and protein kinase C-dependent mechanism. <i>Circulation Research</i> , 2000 , 86, 989-97	15.7	117
16	The p38 MAPK inhibitor, SB203580, abrogates ischaemic preconditioning in rat heart but timing of administration is critical. <i>Basic Research in Cardiology</i> , 2000 , 95, 472-8	11.8	87
15	Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. <i>Journal of Biological Chemistry</i> , 2000 , 275, 8508-14	5.4	180
14	Adenosine A(1) receptor activation induces delayed preconditioning in rats mediated by manganese superoxide dismutase. <i>Circulation</i> , 2000 , 101, 2841-8	16.7	57
13	Insulin administered at reoxygenation exerts a cardioprotective effect in myocytes by a possible anti-apoptotic mechanism. <i>Journal of Molecular and Cellular Cardiology</i> , 2000 , 32, 757-64	5.8	132
12	Ischaemic preconditioning of the vasculature: an overlooked phenomenon for protecting the heart?. <i>Trends in Pharmacological Sciences</i> , 2000 , 21, 225-30	13.2	66
11	Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 2296-302	15.1	108
10	Reperfusion injury revisited: is there a role for growth factor signaling in limiting lethal reperfusion injury?. <i>Trends in Cardiovascular Medicine</i> , 1999 , 9, 245-9	6.9	84
9	Characterisation and validation of a new murine model of global ischaemia-reperfusion injury 1998 , 186, 61-68		30
8	Prolonging the delayed phase of myocardial protection: repetitive adenosine A1 receptor activation maintains rabbit myocardium in a preconditioned state. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 1142-9	15.1	76
7	Phentolamine and preconditioning during coronary angioplasty. <i>Circulation</i> , 1998 , 98, 378-9	16.7	38
6	Renal ischemia preconditions myocardium: role of adenosine receptors and ATP-sensitive potassium channels. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H1542-7	5.2	75
5	Myocardial protection afforded by nicorandil and ischaemic preconditioning in a rabbit infarct model in vivo. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 74-9	3.1	88
4	Genistein, a tyrosine kinase inhibitor, blocks the "second window of protection" 48 h after ischemic preconditioning in the rabbit. <i>Journal of Molecular and Cellular Cardiology</i> , 1997 , 29, 1885-93	5.8	71
3	Editorial Cardiovascular & Renal: Ischaemic preconditioning: rational basis for drug design. <i>Expert Opinion on Investigational Drugs</i> , 1996 , 5, 1435-1442	5.9	
2	Stable high level expression of a transfected human HSP70 gene protects a heart-derived muscle cell line against thermal stress. <i>Journal of Molecular and Cellular Cardiology</i> , 1994 , 26, 695-9	5.8	89

- 1 Hypoxic preconditioning of ischaemic myocardium. *Cardiovascular Research*, **1992**, 26, 556-7 9.9 3